Outcome of Tucidinostat-Based Therapy in HR+ Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitor

Real-World Outcomes of Patients With Metastatic Breast Cancer After Treatment With First-Line ET+CDK4/6i

NCT06975371 ·Status: COMPLETED

Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer

NCT06197581 ·Status: RECRUITING ·Phase: NA

Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.

NCT06961331 ·Status: COMPLETED

Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer

NCT02767661 ·Status: COMPLETED ·Phase: PHASE3

Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor for Postmenopausal Hormone Receptor Positive Breast Cancer

NCT01924078 ·Status: UNKNOWN ·Phase: PHASE2

Study of Etoposide in Treating Patients With Recurrent or Metastatic Breast Cancer

NCT01492556 ·Status: UNKNOWN ·Phase: PHASE2

Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial

NCT05390476 ·Status: UNKNOWN ·Phase: PHASE2

Mitoxantrone Hydrochloride Liposome Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer

NCT06156761 ·Status: NOT_YET_RECRUITING ·Phase: NA

A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

NCT01702571 ·Status: COMPLETED ·Phase: PHASE3

Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer

NCT05955170 ·Status: RECRUITING ·Phase: PHASE2

Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC

NCT04609540 ·Status: UNKNOWN

Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer

NCT03088527 ·Status: COMPLETED ·Phase: PHASE1

Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer

NCT04246502 ·Status: UNKNOWN ·Phase: PHASE2

DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer

NCT04509596 ·Status: COMPLETED ·Phase: PHASE1

Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC

NCT03910712 ·Status: UNKNOWN ·Phase: PHASE2

Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer

NCT00005798 ·Status: COMPLETED ·Phase: PHASE2

Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer

NCT00429182 ·Status: COMPLETED ·Phase: PHASE2

Tipifarnib Plus Tamoxifen in Treating Women With Metastatic Breast Cancer

NCT00052728 ·Status: COMPLETED ·Phase: PHASE2

Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer

NCT05041842 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Pyrotinib Combined With Capecitabine in HER-2 Positive Advanced Breast Cancer and Brain Metastases (Post-PERMEATE)

NCT05359120 ·Status: UNKNOWN

Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy

NCT03201913 ·Status: COMPLETED ·Phase: PHASE1

Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer

NCT03273595 ·Status: UNKNOWN ·Phase: PHASE2

Pyrotinib Combined With Capecitabine and Bevacizumab for Patients With HER2 Positive Breast Cancer and Brain Metastases

NCT06152822 ·Status: RECRUITING ·Phase: PHASE2

Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)

NCT06975644 ·Status: NOT_YET_RECRUITING ·Phase: NA

GW572016 For Treatment Of Refractory Metastatic Breast Cancer

NCT00062686 ·Status: COMPLETED ·Phase: PHASE2